It was observed that more non-GCB DLBCL than GCB-DLBCL exhibited a score of 80% HLA-DRA positivity (Figure 5b), therefore the cutoff for HLA-DRA expression was set at ⩾90% to capture this difference between the COO subtypes and its better prediction of progression-free survival (PFS). The gene discussed is HLA-DRA; the disease is diffuse large B-cell lymphoma.